Skip to main content

Market Overview

Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates

Share:
Curis Shares Drop On Safety Issues From Leukemia Study With CA-4948; Q1 Earnings Missing Estimates
  • Curis Inc (NASDAQ: CRIS) stock gained momentum yesterday in reaction to updated data from its Phase 1/2 study of CA-4948 in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS).
  • Four objective responses were recorded with signs of hematologic recovery.
  • The data published from 15 patients showed bone marrow blast reductions in all tested doses - 200 milligrams, 300 milligrams, and 400 milligrams twice daily.
  • But today, in its Q1 earnings release, the company updated that the 500mg twice daily dosing regimen in the AML/MDS study has exceeded the maximum tolerated dose according to protocol guidelines.
  • Two patients in the cohort were observed to have dose-limiting toxicities, one of whom had severe rhabdomyolysis (breakdown of muscle tissue), and the other experienced severe syncope (fainting or passing ou caused by a temporary drop in the amount of blood that flows to the brain).
  • Both the adverse events resolved after discontinuation of dosing, said the company.
  • Also, the company reported non-clinical data to be presented in a poster at EHA demonstrating synergistic antitumor activity of CA-4948 in combination with azacitidine and venetoclax in leukemia cells.
  • Earnings Update: Curis reported a Q1 EPS loss of $(0.11), which missed the analyst consensus loss estimate of $(0.09) but is narrower than the loss of $(0.280 reported a year ago.
  • Sales of $2.19 million also missed the analyst consensus estimate of $2.64 million and were down 19.2% Y/Y.
  • Cash and equivalents totaled $168.4 million, which is expected to fund its planned operations into 2024.
  • Price Action: CRIS shares dropped 14.9% at $13.85 during the premarket session on the last check Thursday.
 

Related Articles (CRIS)

View Comments and Join the Discussion!

Posted-In: Biotech Earnings News Guidance Health Care Small Cap FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com